A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.

Clark JI, Kuzel TM, Lestingi TM, Fisher SG, Sorokin P, Martone B, Viola M, Sosman JA
Ann Oncol. 2002 13 (4): 606-13

PMID: 12056712 · DOI:10.1093/annonc/mdf105

MeSH Terms (16)

Adult Aged Antineoplastic Combined Chemotherapy Protocols Carcinoma, Renal Cell Drug Administration Schedule Female Humans Interferon-alpha Interferon alpha-2 Interleukin-2 Kidney Neoplasms Male Middle Aged Recombinant Proteins Survival Analysis Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: